Release Details
Coherus BioSciences Management to Present at Two Upcoming Investor Healthcare Conferences
- Management will deliver a company presentation at the Jefferies 2019
London Healthcare Conference onThursday, November 21 st at9:20 a.m. GMT taking place inLondon, UK . - Management will deliver a company presentation at the
Piper Jaffray 31st Annual Healthcare Conference onTuesday, December 3 rd at1:30 p.m. ET taking place inNew York, New York .
The audio portion of the presentations will be available on the investors page of the
About
Coherus is a leading biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales and marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus commercializes UDENYCA® (pegfilgrastim-cbqv) in the U.S. and has received regulatory approval for UDENYCA® in the
Contact
VP, Investor Relations & Corporate Affairs
darrington@coherus.com
+1 (650) 395-0196
Source: Coherus BioSciences, Inc.